Seven-day NIHSS is a sensitive outcome measure for exploratory clinical trials in acute stroke: Evidence from the virtual international stroke trials archive

Stroke

Volumn 43, Issue 5, 2012, Pages 1401-1403

  Kerr, Daniel M ^a   Fulton, Rachael L ^a   Lees, Kennedy R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Clinical trials; Stroke management; Thrombolysis

Indexed keywords

ALTEPLASE;

ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; SAMPLE SIZE; STROKE; TREATMENT INDICATION;

DISABILITY EVALUATION; FIBRINOLYTIC AGENTS; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); OUTCOME ASSESSMENT (HEALTH CARE); RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STROKE; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; UNITED STATES;

EID: 84860113190     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.644484     Document Type: Article

References (9)

1. Quinn TJ, Dawson J, Walters MR, Lees KR. Functional outcome measures in contemporary stroke trials. Int J Stroke. 2009;4:200-205.
2. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
3. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375:1695-1703.
4. Broderick JP, Lu M, Kothari R, Levine SR, Lyden PD, Haley C, et al. Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA Stroke Trial. Stroke. 2000;31: 2335-2341.
5. Ali M, Bath P, Brady M, Davis S, Diener HC, Donnan G, et al. Development, expansion and use of a stroke clinical trials resource for novel exploratory analyses. Int J Stroke. 2012 (in press).
6. Young FB, Weir CJ, Lees KR. Comparison of the National Institutes of Health Stroke Scale with disability outcome measures in acute stroke trials. Stroke. 2005;36:2187-2192. (Pubitemid 41429243)
7. Saver JL. Novel end point analytic techniques and interpreting shifts across the entire range of outcome scales in acute stroke trials. Stroke. 2007;38: 3055-3062. (Pubitemid 350035704)
8. Kasner SE. Clinical interpretation and use of stroke scales. Lancet Neurol. 2006;5:603-612. (Pubitemid 43867434)
9. CPMP. Points to consider on clinical investigation of medicinal products for the treatment of acute stroke, 2001. http://www.ema.europa.eu/docs/en-GB/ document-library/Scientific-guideline/2009/09/WC500003342.pdf. Accessed August 24, 2011.